Education
About Us
Working with TipRanks
Follow Us
AbSci (ABSI)
NASDAQ:ABSI
ABSI Stock Chart & Stats
$2.53
$0.12(3.91%)
At close: 4:00 PM EST
$2.53
$0.12(3.91%)
Day’s Range― - ―
52-Week Range$2.01 - $6.33
Previous CloseN/A
Volume51.94M
Average Volume (3M)3.10M
Market Cap
$437.58M
Enterprise Value$377.18M
Total Cash (Recent Filing)$152.47M
Total Debt (Recent Filing)$6.22M
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Mar 24, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding150,371,540
10 Day Avg. Volume3,142,829
30 Day Avg. Volume3,101,681
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.61
Price to Sales (P/S)63.70
P/FCF Ratio-3.97
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue133.99
Enterprise Value/Gross Profit-7.40
Enterprise Value/Ebitda-3.63
Forecast
1Y Price Target
$7.66Price Target Upside202.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Proof-of-conceptTopline proof-of-concept hair growth data from the ongoing ABS-201 trial could enable accelerated advancement into registrational trials and serve as a clear clinical catalyst.
Differentiated Mechanism Of ActionPreclinical evidence that ABS-201 outperformed topical minoxidil and may provide durable benefit after a short treatment course supports potential commercial differentiation versus existing therapies.
Partnership And Deal PotentialImproving biotech funding conditions and demonstrated strategic interest from large pharmaceutical companies raise the likelihood that positive ABS-201 or TL1A-bispecific data could trigger partnering or acquisition discussions, including possible transaction interest in 1Q26.
Bears Say
Early-stage Efficacy UncertaintyThe program’s current emphasis on safety means clinical efficacy remains unproven and future value depends heavily on upcoming efficacy readouts.
Pipeline Concentration RiskABS-101 was not advanced internally past Phase 1 due to limited pharmacokinetic gains versus newer agents, increasing reliance on ABS-201 to drive pipeline value and external partner interest.
Regulatory And Macro RisksOngoing regulatory uncertainty and broader macro factors could weaken biotech valuations and deal activity, limiting upside even if clinical data are favorable.
AbSci News
ABSI FAQ
What was AbSci’s price range in the past 12 months?
AbSci lowest stock price was $2.01 and its highest was $6.33 in the past 12 months.
What is AbSci’s market cap?
AbSci’s market cap is $437.58M.
When is AbSci’s upcoming earnings report date?
AbSci’s upcoming earnings report date is Mar 24, 2026 which is in 45 days.
How were AbSci’s earnings last quarter?
AbSci released its earnings results on Nov 12, 2025. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.205 by $0.005.
Is AbSci overvalued?
According to Wall Street analysts AbSci’s price is currently Undervalued.
Does AbSci pay dividends?
AbSci does not currently pay dividends.
What is AbSci’s EPS estimate?
AbSci’s EPS estimate is -0.18.
How many shares outstanding does AbSci have?
AbSci has 150,371,540 shares outstanding.
What happened to AbSci’s price movement after its last earnings report?
AbSci reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.205. Following the earnings report the stock price went down -22.353%.
Which hedge fund is a major shareholder of AbSci?
Currently, no hedge funds are holding shares in ABSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbSci Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.66 (202.77% Upside)
$7.66 (202.77% Upside)
Blogger Sentiment
Neutral
ABSI Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $16.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.28%
12-Months-Change
Fundamentals
Return on Equity
-55.68%
Trailing 12-Months
Asset Growth
4.15%
Trailing 12-Months
Company Description
AbSci
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
ABSI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Absci Corporation's strategic focus on expanding its pipeline and leveraging its AI platform for drug discovery. Significant progress was made in the development of ABS-201, with promising market opportunities in AGA and endometriosis. Despite challenges with ABS-101, the company remains financially robust and anticipates new partnerships, indicating a positive outlook.View all ABSI earnings summariesABSI Stock 12 Month Forecast
Average Price Target
$7.66
▲(202.77% Upside)
Technical Analysis
Autolus Therapeutics
―
RAPT Therapeutics
―
ADC Therapeutics
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
7.87% Insiders
19.56% Mutual Funds
23.30% Other Institutional Investors
28.48% Public Companies and Individual Investors